Raymond James analyst C. Gregory Peters raised the firm's price target on HealthEquity ( HQY ) to $120 from $115 and keeps a Strong Buy rating on the shares. HealthEquity's management made considerable progress in Q1 on addressing the fraud activity that plagued the company in the last three quarters, the analyst tells investors in a research note. The firm expects HealthEquity to deliver double digit free cash flow and earnings growth with additional margin expansion through fiscal 2028.